Context: The PNPLA3 I148M variant (rs738409) is robustly associated with hepatic steatosis. Intriguingly, initial findings in cohorts with a mean body mass index (BMI) of 30 kg m À2 also suggested that it is associated with elevated liver enzymes but not with insulin resistance and dyslipidaemia. Objective: To determine whether the PNPLA3 variant alters the susceptibility of morbidly obese subjects to develop liver injury and metabolic sequelae. Participants and methods: The study was carried out in 678 obese Italians (mean BMI ¼ 41 kg m À2 ) who were genotyped for the I148M variant. All participants provided fasting blood samples and then underwent oral glucose tolerance tests. Main outcome measures: Indices of liver injury (alanine transaminase (ALT), aspartate transaminase (AST)), glucose tolerance and insulin resistance were measured. Results: Markers of hepatic injury such as ALT and AST were significantly higher in carriers of the 148M allele (P ¼ 2.2 Â 10 À5 and 0.001, respectively). In all, 50% of 148M risk allele homozygotes had pathological levels of ALT (440 U l À1 ) compared with 25% of 148I allele homozygotes (P ¼ 0.005). Glucose tolerance and insulin sensitivity were similar in all three genotypes. Conclusion: Obese Southern Europeans carrying the 148M allele have increased indices of liver damage uncoupled from proxy measures of insulin resistance.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a burgeoning health problem in Western countries. It has been estimated that 30% of the population in the United States has hepatic steatosis. 1 A body of evidence shows that NAFLD is highly related to obesity and its metabolic consequences such as insulin resistance and dyslipidaemia. 2 In addition to altering metabolic risk, hepatic steatosis is also associated with significant liver disease in some patients. As many as 10-20% of patients with NAFLD develop steatohepatitis 2 and approximately 5% proceed to liver cirrhosis within 10 years of diagnosis. 3 The biological determinants of disease progression are currently poorly understood.
We recently identified 4 a nonsynonymous sequence variation I148M (rs738409) in the PNPLA3 gene. It was strongly associated with increased hepatic fat content in three ethnic groups (African, European Americans and Hispanics, P ¼ 5.9 Â 10
À10
) of the Dallas Heart Study, with the largest effect found in the Hispanics. PNPLA3 is a 481-residue protein with lipase activity in vitro 5, 6 and it is highly expressed in the liver. 6 Moreover, the frequency of the risk allele (148M) mirrored the prevalence of cirrhosis in the three ethnic groups, with highest prevalence again in Hispanics followed by European Americans and African Americans. 4 When alanine transaminase (ALT), a marker of hepatic injury, was evaluated in these populations, an increase in this enzyme was found only in Hispanics. A very recent study replicated the association of the I148M with increased hepatic fat content in an independent Northern European population. 7 We performed genetic association analyses in a large cohort of Italian morbidly obese subjects (mean body mass index (BMI) ¼ 41 kg m À2 ), aiming to evaluate the association between the PNPLA3 I148M variant and ALT levels in a cohort with a higher predisposition to liver disease. Furthermore, given the association between NAFLD and insulin resistance, 8 we also sought to test for an association of the PNPLA3 I148M variant with insulin resistance.
Materials and methods

Patient recruitment
A total of 678 unrelated obese (BMIX30 kg m
À2
) Caucasians were recruited from the Day-Hospital of the Department of Clinical Sciences, University of Rome La Sapienza. They underwent complete medical evaluation and a standard 75 g oral glucose tolerance test with measurements of glucose and insulin at baseline and after 30, 60, 90 and 120 min. Individuals with a daily ethanol consumption of 440 g or a history of viral hepatitis were excluded from the study. Participants were not on glucose-lowering drugs. All individuals provided informed consent prior to inclusion in the study. The study was approved by the local research ethics committee.
Biochemistry
Glucose, insulin, cholesterol, HDL-C and triglycerides were measured as previously described. 9 Serum ALT and aspartate transaminase (AST) levels in fasting subjects were assayed using a Hitachi 737 analyzer (Boehringer-Mannheim Diagnostics, Indianapolis, IN, USA). Homeostatic model assessment of insulin resistance and Insulin Sensitivity Index indices were calculated as previously shown by Matthews et al. 10 and Matsuda et al.
11
Genotyping assay
We developed fluorogenic 5 0 -nucleotidase assays for PNPLA3 rs738409 nonsynonymous sequence variation. The PNPLA3 C to G variant was assayed using the TaqMan assay ID C7241_10 (Applied Biosystems, Foster City, CA, USA) in a total volume of 2.7 ml on a 7900HT Fast Real-Time PCR instrument. The plate was run at 95 1C for 10 min, 92 1C for 15 s and then 60 1C for 1 min for 40 cycles. Allele frequencies were in Hardy-Weinberg equilibrium.
Statistical analysis
Categorical variables were compared using the w 2 test.
Differences between continuous variables were evaluated by analysis of variance, including gender, age and BMI as covariates. Logarithmic transformation was used to normalize distributions of glucose, insulin, homeostatic model assessment of insulin resistance, Insulin Sensitivity Index and plasma triglyceride. All statistical analyses were performed using SPSS 17.0 statistical package.
Results
Association study of the PNPLA3 I148M and transaminase To test whether obesity will expose a PNPLA3 I148M association with ALT in Europeans, we genotyped a large cohort (n ¼ 678) of morbidly obese Italian subjects (mean BMI 41±8 kg m
À2
). The minor allele frequency of the 148M allele was 0.26, which is consistent with that reported for the European Americans of the Dallas Heart Study (minor allele frequency 0.23, P ¼ 0.10).
The clinical characteristics of the study subjects, stratified by genotype, are shown in Table 1 . We found a striking difference in circulating levels of ALT when we compared the three genotypes (Table 1 and Figure 1a ). In particular, individuals with one 148M allele had a small (6%) increase in circulating levels of ALT (Figure 1a ), whereas carriers of rs738409 and liver damage in obese Europeans S Romeo et al two 148M alleles had an B60% increase in ALT levels
). AST is an enzyme also abundantly present in hepatic cells. To confirm the presence of hepatic injury, we also compared AST levels among the PNPLA3 I148M genotypes. We found an increase in AST (Figure 1b ) of 6.5 and 36% in carriers of one and two M alleles, respectively (P ¼ 0.001), which is consistent with the finding of elevated ALT levels. Among our cohort of 678 obese individuals, 78% (n ¼ 529, BMI440 kg m À2 ) were morbidly obese and 22% were only obese (n ¼ 149), with BMI ranging between 30 and 40 kg m À2 . When we performed the same genetic analyses in the two separate groups, we found a similar increase (Supplementary Table 1 ) in mean levels of ALT and AST in carriers of the 148M allele. This increase was statistically significant in all groups (Po0.048 in subjects with a BMIp40 kg m À2 and Po0.001 in subjects with BMI4 40 kg m À2 ).
To assess the clinical relevance of the differences in ALT levels found in carriers of the PNPLA3 148M allele, we evaluated the distribution of the genotypes in individuals with normal and pathological serum levels of ALT (defined as 440 U l
À1
). In all, 50% of the carriers of two 148M alleles had ALT levels above 40 U l À1 compared with 25% of the carriers of two 148I alleles, whereas 30% of heterozygotes had elevated levels of ALT (Figure 2 , P ¼ 0.005). A lower cut-off for ALT levels (o19 U l À1 in women and o30 U À1 in men) to increase the sensitivity in finding individuals with hepatic damage has been proposed by Prati et al. 12 We performed the same analysis according to these criteria, and confirmed the association. In particular, 68, 75 and 86% (P ¼ 0.034) of the individuals with elevated levels of ALT were carrying, respectively, 0, 1 or 2 copies of the risk allele (148M).
To account for possible confounding factors such as use of non-steroidal anti-inflammatory drugs (NSAIDs) and statins, we looked at the distribution of individuals treated with these drugs among the three genotypes and found an even distribution of both class of drugs (P ¼ 0.756 for NSAID, P ¼ 0.881 for statins, Table 1 ). The small number of subjects treated with statins reflects the good control of mean cholesterol in this population, which was also relatively young (43-45 years). Finally, we performed an association analysis on those who were not treated with statins or with NSAIDs, with identical results (data not shown).
Association study of the PNPLA3 I148M and insulin resistance NAFLD is associated with insulin resistance. 2 Carriers of the PNPLA3 I148M allele have more hepatic fat 4, 13 in the liver, and in our obese cohort they have increased circulating levels of ALT and AST. We went on to examine whether carriers of the 148M allele were more insulin resistant or had any impairment in glucose tolerance. Glucose and insulin levels were similar in all three groups throughout the oral glucose tolerance test (Figure 3 ). We also tested for an association with surrogate indices of insulin resistance (homeostatic model assessment of insulin resistance and Matsuda Insulin Sensitivity Index), but no differences were found among genotypes (Table 1) . Circulating triglycerides, total cholesterol and HDL cholesterol levels were also similar among I148M genotypes (Table 1) .
Discussion
The most important finding of this paper is that morbidly obese Southern Europeans carrying the PNPLA3 148M allele have increased levels of ALT and AST without any differences in insulin sensitivity or glucose tolerance. In addition, one out of two individuals with two 148M alleles have pathological ALT levels compared with one out of four carrying two 148I alleles, suggesting that the M allele is associated with a higher risk of hepatic damage.
We previously described a robust association with hepatic fat in African Americans, European Americans and Hispanics rs738409 and liver damage in obese Europeans S Romeo et al of the Dallas Heart Study, with the latter ethnic group having overall more hepatic fat when carrying the 148M allele. We found a strong association with ALT levels and the 148M allele in Hispanics. However, this association was not seen in other ethnic groups. Possible explanations may be that the liver damage is restricted to the Hispanics, or, alternatively, that it is function of the increased hepatic fat in carriers of the 148M allele within this ethnic group. Our specific hypothesis was that substantial excess of body mass would exacerbate the association of the 148M allele with hepatic fat accumulation inducing liver damage, with a subsequent increase in circulating ALT levels. To test this, we used a cohort of morbidly obese Southern Europeans, aiming to test whether a significant increase in total body fat would reveal liver damage in carriers of the 148M allele. We found that carriers of two 148M alleles had a striking increase in both ALT and AST (60 and 36%, respectively). Carriers of one allele showed a more marginal increase in these enzymes (6 and 6.5%, respectively). ALT level is a well established variable to assess liver damage 12, 14 and is commonly used in clinical practice as a marker of steatohepatitis. 15, 16 Current upper limits in the general population are set, on average, at 40 U l
À1
. 15 In terms of the pathological elevation of ALT levels, 50% of all obese Italian PNPLA3 148M homozygotes had abnormal ALT levels compared with 25% who carried two 148I alleles. In addition, using the recently proposed cut-off levels (ALTo19 and 30 U l À1 for women and men, respectively 12 ), individuals with elevated ALT levels were enriched in the 148M allele. We acknowledge that the absence of a direct measure of liver fat content is a limitation of our study. However, association with hepatic triglyceride content in Europeans has been independently replicated. 7 Furthermore, a recent cross-sectional study on 103 individuals with NAFLD documented by liver biopsy showed an enrichment of the 148M allele in the subset with NASH compared with those with hepatic steatosis alone, 17 which is consistent with the increase in transaminase levels in obese carriers that we observed. PNPLA3 is a 481-residue protein highly expressed in the liver 18 and it contains a consensus sequence for a Ser-Asp catalytic dyad (Gly-X-Ser-X-Gly and Asp-X-Gly/Ala), 18 which has lipase activity in vitro. 5, 6 The I148M substitution is located within this consensus sequence and it is highly conserved among species. 4 A possible explanation for the higher transaminase levels is that the reduction in lipase activity caused by I148M substitution may lead to the accumulation of a specific lipotoxic species in the liver, with subsequent cell damage and inflammation. In our study, individuals known to have had viral hepatitis were excluded, although serum HCV and HBV markers were not formally measured in our cohort. It is therefore possible that our results are confounded by concomitant viral infection, but there is no a priori reason to believe that such subjects would be disproportionately present in any particular PNPLA3 genotype class. Another possible confounding factor may be the use of potential hepatotoxic drugs such as statins and NSAIDs. The distribution of individuals treated with both statins and NSAIDs was equal in the three genotypes. In addition, a separate analysis excluding those on both classes of medication did not change the results. Fatty liver is strongly associated with insulin resistance and glucose intolerance. 19, 20 As yet, the direction of the relationship is not entirely clear. Although hyperinsulinaemia can clearly drive hepatic fat accumulation in humans, 21 it is also possible that accumulation of liver fat could impair hepatic insulin action on glucose metabolism. 22 In the Dallas Heart Study we found no differences in fasting glucose and insulin levels among the PNPLA3 genotypes in any of the three ethnic groups studied. 4 Kotronen et al. 7 showed that the relationship between liver fat and directly measured hepatic insulin sensitivity during a hyperinsulinaemiceuglycaemic clamp was not influenced by the three genotype classes. Our study, although using only proxy measures of insulin resistance, did study morbidly obese subjects in whom any specific adverse effect of the PNPLA3 variant on insulin resistance might be expected to be amplified. In this group, consistent with all the previous findings, we found no independent effect of PNPLA3 on glucose or insulin levels or surrogate measures of insulin resistance. Thus, we can rs738409 and liver damage in obese Europeans S Romeo et al tentatively suggest that a genetic variant in PNPLA3 that increases liver fat and predisposes to hepatic damage, particularly in obese individuals, does not have a major independent effect on insulin resistance or circulating levels of plasma lipids. This study also shows how morbid obesity acting as a stressor on a specific genetic background may influence susceptibility to deleterious consequences. PNPLA3 is a protein with lipase activity in vitro; 5, 6 it is highly expressed in the liver 6 and may be involved in triglyceride catabolism in this organ. Further functional studies will be required to assess the physiological role of PNPLA3 in hepatic lipid metabolism and to ascertain whether or not the I148M sequence variation causes the increased hepatic fat content and subsequent hepatocyte damage. A detailed metabolic evaluation of subjects with genetic variants that have a primary impact on hepatic fat levels should help to illuminate the nature of the causative links between insulin resistance, liver fat accumulation and NAFLD.
